WuXi STA, a subsidiary of WuXi AppTec, is a leading CRDMO providing integrated CMC services including both API and drug product for oligonucleotide, peptide and complex conjugate from discovery to development and commercial manufacturing. We have 13 R&D and manufacturing sites across Asia, North America and Europe.
Our CRDMO platform for oligonucleotides and peptides involves their novel monomers payloads and linkers, and complex conjugates. Coupled with injectable formulation development and manufacturing services, including Lipid Nano Particle technology (LNP), we enable global partners to accelerate new therapeutics for patients worldwide.
Oligonucleotides are giving rise to a new generation of therapeutics, and Nitto Avecia is helping lead the way. With more than 25 years’ experience in oligonucleotide development and manufacturing, Nitto Avecia is the partner of choice for pharmaceutical innovators creating new drugs with the power to transform treatment for a wide range of diseases. With the capabilities of Nitto Avecia Pharma Services, Nitto Avecia now offers a comprehensive, end-to-end oligonucleotide solution. This offers the advantage of a single, expert partner handling the entire process from Drug Substance through Drug Product manufacturing with flexible solutions and consistent reliability and quality.
ST Pharm is a pioneer in manufacturing RNA based drugs. Well-proven through decades of business relationships with many big pharmaceutical companies and bio-techs, ST Pharm's reliability in service is the essence of their strength along with their expertise in process development and scale-up optimization.
Asymchem is a global integrated CDMO providing drug R&D and manufacturing for leading pharmaceutical and biotech companies offering solutions ranging from early clinical stage to commercial stage. Asymchem’s oligonucleotide platform provides clients with full services in drug substance, from process development through GMP manufacturing, and drug product, from preformulation development through fill-finish. Additionally, Asymchem can support traditional peptides, pseudopeptides, peptide+linker, peptide-drug conjugates, polymer-drug conjugates, and other highly active peptide molecules. Our analytical team can provide structure characterization, analytical method development, validation, IPC support, final product release testing, and stability study according to ICH requirement.
At ChemGenes, we redefine the limits of scientific discovery, development and commercialization by manufacturing the broadest range of modified chemistries available in today's market. We produce building blocks of life used by scientists and physicians in academic institutions, as well as pharmaceutical and biotechnology companies around the globe, to accelerate breakthroughs, spark innovation and develop lifesaving diagnostics and medicines.